View More Recent Stories

Nov 2, 2017 07:30AM Spark Therapeutics to Participate in Multiple Upcoming Conferences
Oct 31, 2017 07:30AM Spark Therapeutics to Host Conference Call on Tuesday, Nov. 7 at 8:30 a.m. ET to Discuss Third Quarter 2017 Results
Oct 12, 2017 04:52PM Spark Therapeutics (ONCE) Confirms FDA Advisory Committee Unanimously Recommended Approval of LUXTURNA for Patients with Biallelic RPE65-mediated IRD
Oct 12, 2017 04:51PM FDA Advisory Committee Unanimously Recommends Approval of Investigational LUXTURNA™ (voretigene neparvovec) for Patients with Biallelic RPE65-mediated Inherited Retinal Disease
Oct 12, 2017 07:30AM Spark Therapeutics (ONCE) Trading of Stock Halted as FDA Advisory Committee Reviews Investigational Gene Therapy
Oct 3, 2017 07:30AM Spark Therapeutics to Participate in Multiple Conferences in October
Sep 25, 2017 07:32AM Spark Therapeutics (ONCE) Names Federico Mingozzi, Ph.D., as Chief Scientific Officer
Sep 25, 2017 07:30AM Spark Therapeutics Further Expands Gene Therapy Expertise with Appointment of Federico Mingozzi, Ph.D., as Chief Scientific Officer
Sep 20, 2017 07:31AM Spark Therapeutics (ONCE) Announces Licensing Agreement with Genethon
Sep 20, 2017 07:30AM Spark Therapeutics Enters into Licensing Agreement with Genethon
Mar 1, 2017 04:25PM Spark Therapeutics (ONCE), Pfizer (PFE) Announce SPK-9001 Granted Access to PRIME by EMA
Mar 1, 2017 04:15PM Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency
Dec 5, 2016 06:49AM Spark Therapeutics (ONCE), Pfizer (PFE) Announce Prelim. Data from SPK-9001 Phase 1/2 in Hemophilia B
Dec 3, 2016 11:00AM Spark Therapeutics and Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting
Nov 3, 2016 09:06AM Spark Therapeutics (ONCE), Pfizer (PFE) Announce Presentation of Updated SPK-9001 Phase 1/2 data in Hemophilia B
Nov 3, 2016 09:05AM Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity
Jul 25, 2016 08:33AM Spark Therapeutics (ONCE), Pfizer (PFE) Offer Updated SPK-9001 Phase 1/2 Data in Hemophilia B
Jul 25, 2016 08:30AM Spark Therapeutics and Pfizer Announce Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity
Jul 21, 2016 07:32AM Spark Therapeutics (ONCE), Pfizer (PFE) Receive FDA Breakthrough Therapy Designation for SPK-9001 as Hemophilia B Treatment
Jul 21, 2016 07:30AM Spark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B
May 19, 2016 06:31AM Spark Therapeutics (ONCE), Pfizer (PFE) to Present Encouraging SPK-9001 Data at EHA Congress
May 19, 2016 06:30AM Spark Therapeutics and Pfizer Announce Data from Initial Subjects in Hemophilia B Trial Demonstrating Consistent Therapeutic Levels of Factor IX Expression
Oct 12, 2015 09:31AM Pre-Open Stock Movers 10/12: (ESPR) (OREX) (EMC) Higher; (MHR) (SIEN) (LLY) Lower (more...)
Oct 5, 2015 05:26PM Market Wrap: Twitter Affirms Dorsey as CEO; DuPont CEO Kullman to Step Down; Peltz Gets Active on GE
Oct 5, 2015 12:12PM Streetinsider.com's Hot Lunchtime Reads 10/5: (AAPL) (ONCE) (TWTR) (BLUE)
Oct 5, 2015 09:24AM Pre-Open Stock Movers 10/05: (ONCE) (FOLD) (TWTR) Higher; (APP) (FEYE) (VRX) Lower (more...)
Mar 27, 2015 10:00AM Spark Therapeutics, Inc. (Nasdaq: ONCE) to Ring The Nasdaq Stock Market Opening Bell
Mar 27, 2015 10:00AM Spark Therapeutics, Inc. (Nasdaq: ONCE) to Ring The Nasdaq Stock Market Opening Bell
View More Recent Stories